FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380625952> ?p ?o ?g. }

• W4380625952 abstract "Abstract Background and Aims Iron deficiency (ID) in patients with chronic kidney disease (CKD) is highly prevalent and contributes to a poorer quality of life. According to current guidelines, treatment with intravenous (IV) iron is limited to CKD patients with ID and anemia to avoid/delay the use of erythropoiesis-stimulating agents (ESAs) or the reduce the doses of ESA in patients treated with these drugs. Considering the effects of the correction of ID in other settings, we hypothetized that treatment with IV iron in patients with ID and borderline anemia can improve physical performance and their quality of life, independent of the effects on hemoglobin. Method Prospective, unicentric, single-arm study in CKD patients with ID, mild anemia and with-out heart failure. The inclusion criteria were: age ≥ 18 years, CKD patients stages 3–5 not on dialysis, iron deficiency (ferritin &lt;100 ng/ml or ferritin &lt;200 ng/ml if TSAT &lt;20%), mild anaemia (Hb 10.5-11.5 g/dL). At the baseline visit, after all the studies were performed, iv ferric carboxymaltose was administered in a single dose, according to the degree of ID calculated by the Ganzoni´s formula. The co-primary outcome was the change in physical performance, evaluated through the 6 minute-walk test (6MWT) at one week and at four weeks. Secondary end-points: Patient's global assessment (PGA) and quality of life (EQ-5D), Piper's fatigue test, serum phosphorous at four week. Laboratory data, PGA, EQ-5D and Piper test questionnaires were evaluated at baseline, and at weeks 1 and 4 after receiving IV ferric carboximaltose. Results 41 patients completed the study. Primary end-point: the 6MWT increased significantly from 296 ± 101 m to 314 ± 106 m at week 1 (p&lt;0.01), and to 325 ±111 meters at week 4 (p&lt;0.01). at week 4 (p = 0.083). A significant improvement in the PGA test values was detected when compared baseline vs 4 weeks (adjusted p value = 0.031). No significant differences were found between the baseline and week 1 (adjusted p value = 0.083), and week 1 and week 4 visits (adjusted p value = 0.086). No significant differences were found between the initial, 1-week, and 4-week visits in the EQ-5D quality of life questionnaire nor Piper's fatigue test. Phosphorus levels decreased significantly at week 1 from baseline (3.16 ± 0.7 vs 3.72 ± 0.6) (adjusted p&lt;0.001), with a partial recovery of serum levels in week 4 (3.57 ± 0.7 mg/dL). There were no significant increases in hemoglobin concentration between the different time periods. Conclusion IV ferric carboximaltose administration significantly improved the functional capacity of CKD patients with ID in short term. PGA also improved slightly but significantly. Effects that were independent of hemoglobin changes, suggesting a role of ID for a lower physical performance in CKD patients without heart failure, independent of the presence of anemia." @default.
• W4380625952 created "2023-06-15" @default.
• W4380625952 creator A5003986097 @default.
• W4380625952 creator A5007665851 @default.
• W4380625952 creator A5010399718 @default.
• W4380625952 creator A5015472874 @default.
• W4380625952 creator A5033934359 @default.
• W4380625952 creator A5037051923 @default.
• W4380625952 creator A5041110773 @default.
• W4380625952 creator A5041413991 @default.
• W4380625952 creator A5046692355 @default.
• W4380625952 creator A5078413600 @default.
• W4380625952 date "2023-06-01" @default.
• W4380625952 modified "2023-10-16" @default.
• W4380625952 title "#5864 EFFECT OF IV FERRIC CARBOXYMALTOSE ON PHYSICAL PERFORMANCE AND QOL IN PATIENTS WITH CKD NOT ON DIALYSIS, MILD ANEMIA AND IRON DEFICIENCY" @default.
• W4380625952 doi "https://doi.org/10.1093/ndt/gfad063c_5864" @default.
• W4380625952 hasPublicationYear "2023" @default.
• W4380625952 type Work @default.
• W4380625952 citedByCount "0" @default.
• W4380625952 crossrefType "journal-article" @default.
• W4380625952 hasAuthorship W4380625952A5003986097 @default.
• W4380625952 hasAuthorship W4380625952A5007665851 @default.
• W4380625952 hasAuthorship W4380625952A5010399718 @default.
• W4380625952 hasAuthorship W4380625952A5015472874 @default.
• W4380625952 hasAuthorship W4380625952A5033934359 @default.
• W4380625952 hasAuthorship W4380625952A5037051923 @default.
• W4380625952 hasAuthorship W4380625952A5041110773 @default.
• W4380625952 hasAuthorship W4380625952A5041413991 @default.
• W4380625952 hasAuthorship W4380625952A5046692355 @default.
• W4380625952 hasAuthorship W4380625952A5078413600 @default.
• W4380625952 hasBestOaLocation W43806259521 @default.
• W4380625952 hasConcept C126322002 @default.
• W4380625952 hasConcept C159110408 @default.
• W4380625952 hasConcept C187212893 @default.
• W4380625952 hasConcept C2776732101 @default.
• W4380625952 hasConcept C2777417653 @default.
• W4380625952 hasConcept C2778063415 @default.
• W4380625952 hasConcept C2778248108 @default.
• W4380625952 hasConcept C2778319317 @default.
• W4380625952 hasConcept C2778653478 @default.
• W4380625952 hasConcept C2778917026 @default.
• W4380625952 hasConcept C2779951463 @default.
• W4380625952 hasConcept C2779978075 @default.
• W4380625952 hasConcept C71924100 @default.
• W4380625952 hasConcept C90924648 @default.
• W4380625952 hasConceptScore W4380625952C126322002 @default.
• W4380625952 hasConceptScore W4380625952C159110408 @default.
• W4380625952 hasConceptScore W4380625952C187212893 @default.
• W4380625952 hasConceptScore W4380625952C2776732101 @default.
• W4380625952 hasConceptScore W4380625952C2777417653 @default.
• W4380625952 hasConceptScore W4380625952C2778063415 @default.
• W4380625952 hasConceptScore W4380625952C2778248108 @default.
• W4380625952 hasConceptScore W4380625952C2778319317 @default.
• W4380625952 hasConceptScore W4380625952C2778653478 @default.
• W4380625952 hasConceptScore W4380625952C2778917026 @default.
• W4380625952 hasConceptScore W4380625952C2779951463 @default.
• W4380625952 hasConceptScore W4380625952C2779978075 @default.
• W4380625952 hasConceptScore W4380625952C71924100 @default.
• W4380625952 hasConceptScore W4380625952C90924648 @default.
• W4380625952 hasIssue "Supplement_1" @default.
• W4380625952 hasLocation W43806259521 @default.
• W4380625952 hasOpenAccess W4380625952 @default.
• W4380625952 hasPrimaryLocation W43806259521 @default.
• W4380625952 hasRelatedWork W1878595794 @default.
• W4380625952 hasRelatedWork W2285116688 @default.
• W4380625952 hasRelatedWork W2395909070 @default.
• W4380625952 hasRelatedWork W2765128801 @default.
• W4380625952 hasRelatedWork W2795093984 @default.
• W4380625952 hasRelatedWork W2885191723 @default.
• W4380625952 hasRelatedWork W2902763679 @default.
• W4380625952 hasRelatedWork W2908540378 @default.
• W4380625952 hasRelatedWork W2910240063 @default.
• W4380625952 hasRelatedWork W4292831968 @default.
• W4380625952 hasVolume "38" @default.
• W4380625952 isParatext "false" @default.
• W4380625952 isRetracted "false" @default.
• W4380625952 workType "article" @default.